Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team

Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of acce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of medicine (Helsinki) 2021-01, Vol.53 (1), p.1960-1968
Hauptverfasser: Serota, David P., Tookes, Hansel E., Hervera, Belén, Gayle, Babley M., Roeck, Cara R., Suarez, Edward, Forrest, David W., Kolber, Michael A., Bartholomew, Tyler S., Rodriguez, Allan E., Doblecki-Lewis, Susanne
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1968
container_issue 1
container_start_page 1960
container_title Annals of medicine (Helsinki)
container_volume 53
creator Serota, David P.
Tookes, Hansel E.
Hervera, Belén
Gayle, Babley M.
Roeck, Cara R.
Suarez, Edward
Forrest, David W.
Kolber, Michael A.
Bartholomew, Tyler S.
Rodriguez, Allan E.
Doblecki-Lewis, Susanne
description Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of access to harm reduction services. This translates into lengthy hospitalizations with high rates of patient-directed discharge, readmissions, and post-hospitalization mortality. The purpose of this study was to describe the development of an integrated "SIRI Team" and its initial barriers and facilitators to success. The Jackson SIRI Team was developed to improve both hospital and patient-level outcomes for individuals hospitalized with SIRIs at Jackson Memorial Hospital, a 1550-bed public hospital in Miami, Florida, United States. The SIRI Team provides integrated infectious disease and SUD treatment across the healthcare system starting from the inpatient setting and continuing for 90-days post-hospital discharge. The team uses a harm reduction approach, provides care coordination, focuses on access to medications for opioid use disorder (MOUD), and utilizes a variety of infection and addiction treatment modalities to suit each individual patient. Over the initial 8-months of the SIRI Team, 21 patients were treated with 20 surviving until discharge. Infections included osteomyelitis, endocarditis, bacteraemia/fungemia, SSTIs, and septic arthritis. All patients had OUD and 95% used stimulants. All patients were discharged on MOUD and 95% completed their prescribed antibiotic course. At 90-days post-discharge, 25% had been readmitted and 70% reported taking MOUD. A model of integrated infectious disease and SUD care for the treatment of SIRIs has the potential to improve infection and addiction outcomes. Providing attentive, patient-centered care, using a harm reduction approach can facilitate engagement of this marginalized population with the healthcare system. KEY MESSAGES Integrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections. Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.
doi_str_mv 10.1080/07853890.2021.1993326
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_07853890_2021_1993326</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_15b7fdf992e4419ebe50870ad457098d</doaj_id><sourcerecordid>34726095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-c62b889533afc680763b676d1adca140e143edd7d5ad70a3a934c2586b6ac2dc3</originalsourceid><addsrcrecordid>eNp9kdFuFCEUhonR2HX1ETS8wKwwDAzjhdE01a5pYqL1mpyBM91ZZ4YN0DaNLy-z0zb2xivg8P8fCR8hbznbcKbZe1ZrKXTDNiUr-YY3jRClekZWXChZlEyx52Q1Z4o5dEJexbhnjJU1Zy_JiajqUrFGrsifcwgjDeiuber9RDsfaNohTQEhjTgl6jt6gNTnbaS3fdrRiDcYkPbTHo-dIuAACV2edMskfqAOow394cjMhBn5DezvmI8_tz-29BJhfE1edDBEfHO_rsmvL2eXp-fFxfev29PPF4WVokqFVWWrdSOFgM4qzWolWlUrx8FZ4BVDXgl0rnYSXM1AQCMqW0qtWgW2dFasyXbhOg97cwj9COHOeOjNceDDlYGQejug4bKtO9c1TYlVxRtsUTKdoa6SNWu0y6yPC-tw3Y7obP6WAMMT6NObqd-ZK39jtFS1zsrWRC4AG3yMAbvHLmdmNmsezJrZrLk3m3vv_n34sfWgMgc-LYGswYcRbn0YnElwN_jQBZhsH434_xt_AXQQteY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team</title><source>Taylor &amp; Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Serota, David P. ; Tookes, Hansel E. ; Hervera, Belén ; Gayle, Babley M. ; Roeck, Cara R. ; Suarez, Edward ; Forrest, David W. ; Kolber, Michael A. ; Bartholomew, Tyler S. ; Rodriguez, Allan E. ; Doblecki-Lewis, Susanne</creator><creatorcontrib>Serota, David P. ; Tookes, Hansel E. ; Hervera, Belén ; Gayle, Babley M. ; Roeck, Cara R. ; Suarez, Edward ; Forrest, David W. ; Kolber, Michael A. ; Bartholomew, Tyler S. ; Rodriguez, Allan E. ; Doblecki-Lewis, Susanne</creatorcontrib><description>Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of access to harm reduction services. This translates into lengthy hospitalizations with high rates of patient-directed discharge, readmissions, and post-hospitalization mortality. The purpose of this study was to describe the development of an integrated "SIRI Team" and its initial barriers and facilitators to success. The Jackson SIRI Team was developed to improve both hospital and patient-level outcomes for individuals hospitalized with SIRIs at Jackson Memorial Hospital, a 1550-bed public hospital in Miami, Florida, United States. The SIRI Team provides integrated infectious disease and SUD treatment across the healthcare system starting from the inpatient setting and continuing for 90-days post-hospital discharge. The team uses a harm reduction approach, provides care coordination, focuses on access to medications for opioid use disorder (MOUD), and utilizes a variety of infection and addiction treatment modalities to suit each individual patient. Over the initial 8-months of the SIRI Team, 21 patients were treated with 20 surviving until discharge. Infections included osteomyelitis, endocarditis, bacteraemia/fungemia, SSTIs, and septic arthritis. All patients had OUD and 95% used stimulants. All patients were discharged on MOUD and 95% completed their prescribed antibiotic course. At 90-days post-discharge, 25% had been readmitted and 70% reported taking MOUD. A model of integrated infectious disease and SUD care for the treatment of SIRIs has the potential to improve infection and addiction outcomes. Providing attentive, patient-centered care, using a harm reduction approach can facilitate engagement of this marginalized population with the healthcare system. KEY MESSAGES Integrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections. Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.</description><identifier>ISSN: 0785-3890</identifier><identifier>EISSN: 1365-2060</identifier><identifier>DOI: 10.1080/07853890.2021.1993326</identifier><identifier>PMID: 34726095</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Addiction ; Adult ; Aftercare ; Anti-Bacterial Agents - therapeutic use ; Endocarditis ; Endocarditis - diagnosis ; Endocarditis - epidemiology ; Endocarditis - microbiology ; Female ; Harm Reduction ; Humans ; Injection Site Reaction - epidemiology ; Male ; opioid use disorder ; Opioid-Related Disorders - complications ; Osteomyelitis - diagnosis ; Osteomyelitis - epidemiology ; Osteomyelitis - etiology ; Osteomyelitis - microbiology ; Patient Discharge ; skin and soft tissue infection ; Soft Tissue Infections - drug therapy ; Substance Abuse, Intravenous - complications ; substance use disorder ; Syringes ; United States - epidemiology</subject><ispartof>Annals of medicine (Helsinki), 2021-01, Vol.53 (1), p.1960-1968</ispartof><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2021</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-c62b889533afc680763b676d1adca140e143edd7d5ad70a3a934c2586b6ac2dc3</citedby><cites>FETCH-LOGICAL-c534t-c62b889533afc680763b676d1adca140e143edd7d5ad70a3a934c2586b6ac2dc3</cites><orcidid>0000-0002-9384-0812</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567885/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567885/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34726095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serota, David P.</creatorcontrib><creatorcontrib>Tookes, Hansel E.</creatorcontrib><creatorcontrib>Hervera, Belén</creatorcontrib><creatorcontrib>Gayle, Babley M.</creatorcontrib><creatorcontrib>Roeck, Cara R.</creatorcontrib><creatorcontrib>Suarez, Edward</creatorcontrib><creatorcontrib>Forrest, David W.</creatorcontrib><creatorcontrib>Kolber, Michael A.</creatorcontrib><creatorcontrib>Bartholomew, Tyler S.</creatorcontrib><creatorcontrib>Rodriguez, Allan E.</creatorcontrib><creatorcontrib>Doblecki-Lewis, Susanne</creatorcontrib><title>Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team</title><title>Annals of medicine (Helsinki)</title><addtitle>Ann Med</addtitle><description>Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of access to harm reduction services. This translates into lengthy hospitalizations with high rates of patient-directed discharge, readmissions, and post-hospitalization mortality. The purpose of this study was to describe the development of an integrated "SIRI Team" and its initial barriers and facilitators to success. The Jackson SIRI Team was developed to improve both hospital and patient-level outcomes for individuals hospitalized with SIRIs at Jackson Memorial Hospital, a 1550-bed public hospital in Miami, Florida, United States. The SIRI Team provides integrated infectious disease and SUD treatment across the healthcare system starting from the inpatient setting and continuing for 90-days post-hospital discharge. The team uses a harm reduction approach, provides care coordination, focuses on access to medications for opioid use disorder (MOUD), and utilizes a variety of infection and addiction treatment modalities to suit each individual patient. Over the initial 8-months of the SIRI Team, 21 patients were treated with 20 surviving until discharge. Infections included osteomyelitis, endocarditis, bacteraemia/fungemia, SSTIs, and septic arthritis. All patients had OUD and 95% used stimulants. All patients were discharged on MOUD and 95% completed their prescribed antibiotic course. At 90-days post-discharge, 25% had been readmitted and 70% reported taking MOUD. A model of integrated infectious disease and SUD care for the treatment of SIRIs has the potential to improve infection and addiction outcomes. Providing attentive, patient-centered care, using a harm reduction approach can facilitate engagement of this marginalized population with the healthcare system. KEY MESSAGES Integrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections. Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.</description><subject>Addiction</subject><subject>Adult</subject><subject>Aftercare</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Endocarditis</subject><subject>Endocarditis - diagnosis</subject><subject>Endocarditis - epidemiology</subject><subject>Endocarditis - microbiology</subject><subject>Female</subject><subject>Harm Reduction</subject><subject>Humans</subject><subject>Injection Site Reaction - epidemiology</subject><subject>Male</subject><subject>opioid use disorder</subject><subject>Opioid-Related Disorders - complications</subject><subject>Osteomyelitis - diagnosis</subject><subject>Osteomyelitis - epidemiology</subject><subject>Osteomyelitis - etiology</subject><subject>Osteomyelitis - microbiology</subject><subject>Patient Discharge</subject><subject>skin and soft tissue infection</subject><subject>Soft Tissue Infections - drug therapy</subject><subject>Substance Abuse, Intravenous - complications</subject><subject>substance use disorder</subject><subject>Syringes</subject><subject>United States - epidemiology</subject><issn>0785-3890</issn><issn>1365-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kdFuFCEUhonR2HX1ETS8wKwwDAzjhdE01a5pYqL1mpyBM91ZZ4YN0DaNLy-z0zb2xivg8P8fCR8hbznbcKbZe1ZrKXTDNiUr-YY3jRClekZWXChZlEyx52Q1Z4o5dEJexbhnjJU1Zy_JiajqUrFGrsifcwgjDeiuber9RDsfaNohTQEhjTgl6jt6gNTnbaS3fdrRiDcYkPbTHo-dIuAACV2edMskfqAOow394cjMhBn5DezvmI8_tz-29BJhfE1edDBEfHO_rsmvL2eXp-fFxfev29PPF4WVokqFVWWrdSOFgM4qzWolWlUrx8FZ4BVDXgl0rnYSXM1AQCMqW0qtWgW2dFasyXbhOg97cwj9COHOeOjNceDDlYGQejug4bKtO9c1TYlVxRtsUTKdoa6SNWu0y6yPC-tw3Y7obP6WAMMT6NObqd-ZK39jtFS1zsrWRC4AG3yMAbvHLmdmNmsezJrZrLk3m3vv_n34sfWgMgc-LYGswYcRbn0YnElwN_jQBZhsH434_xt_AXQQteY</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Serota, David P.</creator><creator>Tookes, Hansel E.</creator><creator>Hervera, Belén</creator><creator>Gayle, Babley M.</creator><creator>Roeck, Cara R.</creator><creator>Suarez, Edward</creator><creator>Forrest, David W.</creator><creator>Kolber, Michael A.</creator><creator>Bartholomew, Tyler S.</creator><creator>Rodriguez, Allan E.</creator><creator>Doblecki-Lewis, Susanne</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9384-0812</orcidid></search><sort><creationdate>20210101</creationdate><title>Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team</title><author>Serota, David P. ; Tookes, Hansel E. ; Hervera, Belén ; Gayle, Babley M. ; Roeck, Cara R. ; Suarez, Edward ; Forrest, David W. ; Kolber, Michael A. ; Bartholomew, Tyler S. ; Rodriguez, Allan E. ; Doblecki-Lewis, Susanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-c62b889533afc680763b676d1adca140e143edd7d5ad70a3a934c2586b6ac2dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Addiction</topic><topic>Adult</topic><topic>Aftercare</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Endocarditis</topic><topic>Endocarditis - diagnosis</topic><topic>Endocarditis - epidemiology</topic><topic>Endocarditis - microbiology</topic><topic>Female</topic><topic>Harm Reduction</topic><topic>Humans</topic><topic>Injection Site Reaction - epidemiology</topic><topic>Male</topic><topic>opioid use disorder</topic><topic>Opioid-Related Disorders - complications</topic><topic>Osteomyelitis - diagnosis</topic><topic>Osteomyelitis - epidemiology</topic><topic>Osteomyelitis - etiology</topic><topic>Osteomyelitis - microbiology</topic><topic>Patient Discharge</topic><topic>skin and soft tissue infection</topic><topic>Soft Tissue Infections - drug therapy</topic><topic>Substance Abuse, Intravenous - complications</topic><topic>substance use disorder</topic><topic>Syringes</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serota, David P.</creatorcontrib><creatorcontrib>Tookes, Hansel E.</creatorcontrib><creatorcontrib>Hervera, Belén</creatorcontrib><creatorcontrib>Gayle, Babley M.</creatorcontrib><creatorcontrib>Roeck, Cara R.</creatorcontrib><creatorcontrib>Suarez, Edward</creatorcontrib><creatorcontrib>Forrest, David W.</creatorcontrib><creatorcontrib>Kolber, Michael A.</creatorcontrib><creatorcontrib>Bartholomew, Tyler S.</creatorcontrib><creatorcontrib>Rodriguez, Allan E.</creatorcontrib><creatorcontrib>Doblecki-Lewis, Susanne</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Annals of medicine (Helsinki)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serota, David P.</au><au>Tookes, Hansel E.</au><au>Hervera, Belén</au><au>Gayle, Babley M.</au><au>Roeck, Cara R.</au><au>Suarez, Edward</au><au>Forrest, David W.</au><au>Kolber, Michael A.</au><au>Bartholomew, Tyler S.</au><au>Rodriguez, Allan E.</au><au>Doblecki-Lewis, Susanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team</atitle><jtitle>Annals of medicine (Helsinki)</jtitle><addtitle>Ann Med</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>53</volume><issue>1</issue><spage>1960</spage><epage>1968</epage><pages>1960-1968</pages><issn>0785-3890</issn><eissn>1365-2060</eissn><abstract>Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of access to harm reduction services. This translates into lengthy hospitalizations with high rates of patient-directed discharge, readmissions, and post-hospitalization mortality. The purpose of this study was to describe the development of an integrated "SIRI Team" and its initial barriers and facilitators to success. The Jackson SIRI Team was developed to improve both hospital and patient-level outcomes for individuals hospitalized with SIRIs at Jackson Memorial Hospital, a 1550-bed public hospital in Miami, Florida, United States. The SIRI Team provides integrated infectious disease and SUD treatment across the healthcare system starting from the inpatient setting and continuing for 90-days post-hospital discharge. The team uses a harm reduction approach, provides care coordination, focuses on access to medications for opioid use disorder (MOUD), and utilizes a variety of infection and addiction treatment modalities to suit each individual patient. Over the initial 8-months of the SIRI Team, 21 patients were treated with 20 surviving until discharge. Infections included osteomyelitis, endocarditis, bacteraemia/fungemia, SSTIs, and septic arthritis. All patients had OUD and 95% used stimulants. All patients were discharged on MOUD and 95% completed their prescribed antibiotic course. At 90-days post-discharge, 25% had been readmitted and 70% reported taking MOUD. A model of integrated infectious disease and SUD care for the treatment of SIRIs has the potential to improve infection and addiction outcomes. Providing attentive, patient-centered care, using a harm reduction approach can facilitate engagement of this marginalized population with the healthcare system. KEY MESSAGES Integrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections. Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>34726095</pmid><doi>10.1080/07853890.2021.1993326</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9384-0812</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0785-3890
ispartof Annals of medicine (Helsinki), 2021-01, Vol.53 (1), p.1960-1968
issn 0785-3890
1365-2060
language eng
recordid cdi_crossref_primary_10_1080_07853890_2021_1993326
source Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Addiction
Adult
Aftercare
Anti-Bacterial Agents - therapeutic use
Endocarditis
Endocarditis - diagnosis
Endocarditis - epidemiology
Endocarditis - microbiology
Female
Harm Reduction
Humans
Injection Site Reaction - epidemiology
Male
opioid use disorder
Opioid-Related Disorders - complications
Osteomyelitis - diagnosis
Osteomyelitis - epidemiology
Osteomyelitis - etiology
Osteomyelitis - microbiology
Patient Discharge
skin and soft tissue infection
Soft Tissue Infections - drug therapy
Substance Abuse, Intravenous - complications
substance use disorder
Syringes
United States - epidemiology
title Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A32%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Harm%20reduction%20for%20the%20treatment%20of%20patients%20with%20severe%20injection-related%20infections:%20description%20of%20the%20Jackson%20SIRI%20Team&rft.jtitle=Annals%20of%20medicine%20(Helsinki)&rft.au=Serota,%20David%20P.&rft.date=2021-01-01&rft.volume=53&rft.issue=1&rft.spage=1960&rft.epage=1968&rft.pages=1960-1968&rft.issn=0785-3890&rft.eissn=1365-2060&rft_id=info:doi/10.1080/07853890.2021.1993326&rft_dat=%3Cpubmed_cross%3E34726095%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34726095&rft_doaj_id=oai_doaj_org_article_15b7fdf992e4419ebe50870ad457098d&rfr_iscdi=true